In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Dehydrobenzperidol; Droleptan; Droperidol; Inapsin; Inapsine (Akorn); Sintodian; Xomolix (ProStrakan)
- INDICATIONS: Tranquilizer and antiemetic in surgical procedures
- CLASS: Antiemetic, Antipsychotic, Butyrophenone
- HALF-LIFE: 2.3 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amisulpride, Amitriptyline, Arsenic, Atomoxetine, Azithromycin, Chloroquine, CNS depressants, Cyclobenzaprine, Disopyramide, Duloxetine, Eszopiclone, Fluoxetine, Fluvoxamine, Hydromorphone, Hydroxychloroquine, Levomepromazine, Lurasidone, Macrolides, Metaxalone, Milnacipran, Moxifloxacin, Paliperidone, Pentamidine, Pimozide, QT prolonging agents, Quinine, Ramelteon, Sertraline, Sotalol, Sulpiride / levosulpiride, Tamoxifen, Tapentadol, Thiopental, Tiagabine, Tricyclic antidepressants
- See adverse reactions attributed to class:
Contra-indicated in patients with known or suspected QT prolongation.
This product is not available in the European market.
QT PROLONGATION AND TORSADE DE POINTES
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
